BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35373264)

  • 1. Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data.
    Wang X; Cho-Phan CD; Hoskins KF; Calip GS
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):704-706. PubMed ID: 35373264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
    Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
    Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
    J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
    Ibraheem A; Olopade OI; Huo D
    Cancer; 2020 Sep; 126(17):4013-4022. PubMed ID: 32521056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?
    Freeman JQ; Huo D
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):635-637. PubMed ID: 38689576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
    Hoskins KF; Danciu OC; Ko NY; Calip GS
    JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
    Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
    J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
    Carlson JJ; Roth JA
    Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
    Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
    Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study.
    Nam G; Singh K; Lopresti ML; Ouseph MM; Wang LJ; Wang Y
    Technol Cancer Res Treat; 2021; 20():15330338211035037. PubMed ID: 34696631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
    Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
    Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
    Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
    Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncotype DX and Prosigna in breast cancer patients: A comparison study.
    Abdelhakam DA; Hanna H; Nassar A
    Cancer Treat Res Commun; 2021; 26():100306. PubMed ID: 33444922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
    Rizki H; Hillyar C; Abbassi O; Miles-Dua S
    Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
    Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
    Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.